Availability of CVD Meds Varies by Low-Cost Generic Program
WEDNESDAY, Sept. 6, 2023 (HealthDay News) — For six cardiovascular diseases (CVDs) examined, coverage of evidence-based medications varies by low-cost generic program (LCGP), drug, and condition, according to a study published online Sept. 5 in the A…
Learn MoreOOP Costs Often Exceed Discount Card Pricing for Select Generics
WEDNESDAY, Sept. 6, 2023 (HealthDay News) — For select generic medications, out-of-pocket (OOP) payments frequently exceed discount card pricing for two discount drug programs, according to a research letter published online Sept. 5 in the Annals of …
Learn MoreIn-Hospital Adverse Events Similar for Haloperidol, Atypical Antipsychotics
WEDNESDAY, Sept. 6, 2023 (HealthDay News) — For older patients without psychiatric disorders prescribed oral antipsychotic drugs after major surgery, the risks for in-hospital adverse events are comparable for haloperidol and atypical antipsychotics,…
Learn MoreApixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
TUESDAY, Sept. 5, 2023 (HealthDay News) — Apixaban has a lower bleeding risk than warfarin or rivaroxaban during initial treatment for patients with venous thromboembolism (VTE), according to a study published online Aug. 28 in the Journal of Interna…
Learn MoreMost of the Effect of Paroxetine for Treating Hot Flashes May Be Placebo Effect
TUESDAY, Sept. 5, 2023 (HealthDay News) — Most of the efficacy of paroxetine to treat hot flashes may be a placebo effect, according to a review published online Aug. 4 in Frontiers in Psychiatry.Joshua R. Rhodes, Ph.D., from Abilene Christian Univer…
Learn MoreConcizumab May Be Effective Prophylaxis for Hemophilia A or B With Inhibitors
FRIDAY, Sept. 1, 2023 (HealthDay News) — Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal …
Learn MoreRates of Tx Retention for Rifaximin Low Despite Benefits for Hepatic Encephalopathy
FRIDAY, Sept. 1, 2023 (HealthDay News) — Rates of rifaximin treatment retention are low despite the known benefits of rifaximin use for breakthrough hepatic encephalopathy (HE), according to a study published in the August issue of Hepatology Communi…
Learn MoreSegún la Casa Blanca, Medicare negociará los precios de los fármacos cardiacos, para la diabetes y el cáncer
MARTES, 29 de agosto de 2023 (HealthDay News) — El martes, la administración de Biden especificó los 10 primeros medicamentos que se incluirán en las negociaciones sobre los precios entre Medicare y las compañías farmacéuticas participantes. La lista…
Learn MoreHeart, Diabetes, Cancer Drugs on List for Medicare Price Negotiations, White House Says
TUESDAY, Aug. 29, 2023 (HealthDay News) — The Biden administration on Tuesday named the first 10 medicines that will be subject to price negotiations between Medicare and participating drug companies as a first step in a landmark program aimed at red…
Learn MoreHeart, Diabetes, Cancer Drugs on List for Medicare Price Negotiations, White House Says
TUESDAY, Aug. 29, 2023 (HealthDay News) — The Biden administration on Tuesday named the first 10 medicines that will be subject to price negotiations between Medicare and participating drug companies.The list represents the first step in a landmark p…
Learn More